Introduction
The DNA binding activity described as AP-1 (activating protein-1) represents dimers of the Jun (c-Jun, JunB and JunD), Fos (c-Fos, FosB, Fra1 and Fra2), or CREB/ATF (CREB, ATF2, ATF3/LRF1, CREB, Mafs and others) superfamily of proteins (reviewed in Vogt et al., 1990; Angel and Karin, 1991; Karin et al., 1997) . AP-1 components form dimers through leucine zipper (ZIP) motifs and bind DNA through basic amino acids (b) that are contiguous with the ZIP domains of the molecules (Kerppola and Curran, 1991; Glover and Harrison 1995) . Homodimers or heterodimers comprised of members of this extended family of bZIP proteins bind closely related DNA sites referred to as the TRE (for 12-O-tetradecanolyphorbol-13-acetate-response element) or the CRE (cyclic AMP-response element). Jun/Fos dimers preferentially bind to TREs while complexes containing ATFs bind preferentially to CREs (Hai and Curran, 1991) .
In recent years, a number of new bZIP proteins have been identi®ed that associate speci®cally with Jun and/ or Fos. The bZIP protein ATF3/LRF-1 forms dimers with Jun, not Fos, to generate a complex that binds and activates expression of the tissue-speci®c proenkephalon gene through CRE sites (Hsu et al., 1991) . Interestingly, as a homodimer, ATF3/LRF-1 also binds CRE sites, yet functions as a transcriptional repressor . c-Maf and the neural retina bZIP protein NRL form heterodimers with either Fos or Jun (Kerppola and Curran, 1994) and activate transcription by binding MAREs ± extended AP-1 sites that contain a TRE or a CRE (Kataoka et al., 1994) . Fos-speci®c dimerization is a feature of the small Maf proteins (MafF, MafG and MafK) which, unlike c-Maf, do not encode a transcription activation domain (Fujiwara et al., 1993; Kataoka et al., 1994) . Most recently, two novel proteins called JDP1 and JDP2 were identi®ed as speci®c dimerization partners for Jun (Aronheim et al., 1997) . The role of these proteins in cellular events has yet to be determined.
The existence of so many AP-1 components presumbably re¯ects a mechanism by which gene targets under AP-1 transcriptional control are regulated in a growth-speci®c and/or a tissue-speci®c manner. Indeed, while AP-1 activity was de®ned originally as the transcription complex playing a crucial role in up-regulating gene expression following the stimulation of quiescent cells with growth factors (reviewed in Angel and , it is now recognized that AP-1 DNA binding activity is maintained in quiescent cells (Pfarr et al., 1994) , directs certain cells to dierentiate (Grigoriadis et al., 1993; Pfarr et al., 1994) and plays a role in programmed cell death (Colotta et al., 1992; Smeyne et al., 1993; Ham et al., 1995; Bossy-Wetzel et al., 1997; Wisdom et al., 1999) . Clearly, it is the participation of speci®c subunits in AP-1, combined with the in¯uence of post-translational protein modi®cations on the activities of these subunits (reviewed in Karin et al., 1997) , that determines whether AP-1 functions as a transcriptional activator or repressor toward a speci®c target gene. In agreement with this, the small Maf proteins, when dimerized with Fos, are transcriptionally inactive and function to block erythroid dierentiation by competing for the DNA binding sites that become occupied by transcriptionally active Maf/NF-E2 complexes in erythrocytes (Kataoka et al., 1995) . Similarly, as NIH3T3 ®broblasts undergo growth arrest, or as 3T3T adipocytes dierentiate, the level of c-Jun decreases concomitant with an increase in JunD, suggesting opposing cellular roles for AP-1 complexes containing c-Jun or JunD (Pfarr et al., 1994; Wang et al., 1996) .
In 1995, our laboratory isolated a cDNA from a human B cell library that encodes a 125 amino acid nuclear-localized protein with a central bZIP domain displaying a high degree of sequence similarity to the AP-1/ATF superfamily of bZIP transcription factors (Dorsey et al., 1995) . We called this protein B-ATF and have shown that it does not form homodimers, does not dimerize with Fos, but does form heterodimers with the Jun family of proteins (c-Jun, JunD, and JunB) to bind AP-1 (TRE) consensus DNA sites (Dorsey et al., 1995) . B-ATF mRNA is expressed at detectable levels in very few human tissues, with the highest levels of expression restricted to hematopoietic tissues. In this paper, we present data showing that B-ATF does not contain a functional transcription activation domain and that Jun/B-ATF heterodimers are transcriptionally inert. The ability of B-ATF to function as a dominant-negative to AP-1 is revealed by standard transcription activation assays and by the ability of forced expression of B-ATF to slow the growth of ®broblasts and to dramatically reduce transformation of these cells by the v-fos or H-ras oncogenes. Expression of a fusion protein in which B-ATF is linked to the potent transcription activation domain of the herpes simplex virus VP16 protein augments reporter gene expression by Fos and Jun and enhances focus formation by H-ras. This con®rms the functional participation of B-ATF in cellular AP-1 complexes and suggests that, in hematopoietic cells where B-ATF is normally expressed, the novel properties of this bZIP protein contribute to the modulation of AP-1 activity that is critical to cell lineage establishment and expansion (reviewed in Foletta et al., 1998) .
Results

B-ATF mRNA is expressed predominantly in hematopoietic tissues and cell lines
The B-ATF cDNA was isolated from an EBVimmortalized human B cell cDNA library. Using a yeast two-hybrid screen with B-ATF as the bait protein and the same B cell cDNA library as the source of interacting protein partners, we found that JunB served as a speci®c dimerization partner of B-ATF (Dorsey et al., 1995) . Follow-up studies by our lab and another revealed that B-ATF mRNA expression is restricted to EBV-positive B cell lines such as Raji and 721 and to human T lymphocyte cell lines such as Jurkat and Sup-T1 (Hasewaga et al., 1996; Johansen and Taparowsky, manuscript in preparation) . In an eort to survey the level of B-ATF gene expression in various human blood forming tissues, a Northern blot of poly A + mRNA isolated from one fetal and six adult tissues was probed with a 32 P-labeled, B-ATF cDNA fragment ( Figure 1, top panel) . B-ATF mRNA expression is moderate in the spleen, lymph nodes, appendix and peripheral blood, is low in the thymus and bone marrow samples, and is not detected in fetal liver. This restricted pattern of B-ATF gene expression indicates that B-ATF mRNA is associated with the later stages of myeloid and lymphoid lineage development and is not a feature of developing erythrocytes. To investigate how the pattern of junB mRNA expression compares to B-ATF in these tissues, the ®lter was stripped and reprobed with a junB cDNA fragment. As shown in Figure 1 (middle panel), the level of junB mRNA expression is more widespread and generally higher than B-ATF. JunB mRNA is abundant in peripheral blood and, like B-ATF, is expressed moderately in spleen, lymph nodes and appendix. Lower, yet detectable, amounts of junB mRNA also are observed in the thymus and in fetal liver. These expression data were interpreted using control hybridization signals generated from a labeled DNA probe speci®c for the constitutively expressed G 3 PDH mRNA (Figure 1 , bottom panel).
B-ATF does not contain a transcription activation domain
The B-ATF protein is one of the smallest nuclear bZIP proteins identi®ed to data and consists of a basic leucine zipper domain¯anked by 29 amino terminal residues and 50 carboxyl terminal amino acids. The Figure 1 B-ATF is expressed in human hematopoietic tissues. Northern blot hybridization of poly A + mRNA isolated from human hematopoietic tissues was performed as described in Materials and methods. The top panel shows the results of hybridizing with a radiolabeled fragment of the B-ATF cDNA and reveals the presence of B-ATF transcripts in all samples except fetal liver. The blot was stripped and subsequently hybridized with a human junB cDNA probe to assess expression of this B-ATF dimerization partner in these same tissues (middle panel). The blot was stripped a second time and hybridized with a G 3 PDH probe to check the amount and integrity of the mRNA loaded in each lane. RNA size markers are indicated to the left of the exposures showing B-ATF and junB mRNA expression ability of B-ATF to form heterodimers with JunB, cJun and JunD and bind AP-1 DNA sites (Dorsey et al., 1995) suggests that B-ATF plays a role in the cellular activities of AP-1 perhaps by altering transcription activation by Jun. To determine if B-ATF possesses a functional transcription activation domain (TAD), various portions of the B-ATF protein were expressed as fusions with the DNA binding domain (DB) of the yeast GAL4 protein (Figure 2 ). C3H10T1/2 cells were transiently transfected as described in Materials and methods with each GAL4 DB activator and a chloramphenicol acetyl transferase (CAT) reporter plasmid containing ®ve tandem GAL4 protein binding sites. Basal transcription activation by GAL4 DB alone was set to 1.00 and the level of CAT activity generated by the well-characterized chimeric activator GAL4 DB-E1A served as the positive control ( Figure  2 ). Neither the full-length B-ATF protein (1 ± 125), nor fusion proteins containing the amino-or carboxylterminal portion of B-ATF, were able to stimulate signi®cant (GAL4) 5 CAT reporter gene expression in C3H10T1/2 cells. Western blot analysis of the cell extracts demonstrated that all of the activators used in this experiment were expressed to comparable levels (data not shown). These data support our prior observation that GAL4 DB-B-ATF(1 ± 125) does not activate transcription in Saccharomyces cerevisae (Dorsey et al., 1995) and suggest that the participation of B-ATF in AP-1 complexes is unlikely to enhance transcription. Instead, B-ATF may function as a dominant-negative to block AP-1-mediated gene expression in cells.
B-ATF interacts with JunB through the B-ATF leucine zipper motif
The ability of JunB and B-ATF to interact is assumed to be mediated by the amphipathic a-helical leucine zipper motifs present in each protein. To test this hypothesis and to demonstrate a two-hybrid, proteinprotein interaction between JunB and B-ATF in mammalian cells, we generated a vector expressing amino acids 1 ± 347 of JunB as a GAL4 DB fusion protein and ®ve additional plasmids expressing overlapping portions of B-ATF as fusions with the transactivation domain (TAD) of herpes simplex virus VP16 (Figure 3 ). C3H10T1/2 cells were transiently transfected with (GAL4) 5 CAT, GAL4 DB-JunB and each TAD-B-ATF protein as described in Materials and methods. For these assays, CAT expression stimulated by the potent chimeric activator GAL4 DB-VP16 was set to 100% and co-expression of GAL4 DB-JunB and the VP16 TAD, or of GAL4 DB and B-ATF (1 ± 125) TAD, served as the negative controls (0.5 and 0.7% of GAL4 DB-VP16, respectively). Signi®cant levels of CAT activity were observed only when TAD fusions representing full-length B-ATF (amino acids 1 ± 125) or an amino terminal truncation of B-ATF (amino acids 49 ± 125) containing the leucine zipper domain (amino acids 54 ± 81) were co-expressed with GAL4 DB-JunB. The strength of the mammalian two-hybrid interaction between JunB and B-ATF is relatively low when compared to the CAT activity generated by a monomeric activator (e.g. GAL4 DB-VP16). However, in control experiments, we observed that the Jun/B-ATF interaction results in a level of activation that is at least twofold higher than that produced from the interaction of two well-characterized dimerization partners, Myc and Max (data not shown). Therefore, we conclude that in mammalian cells expressing both JunB and B-ATF, direct proteinprotein interaction is possible and is mediated by the leucine zipper region of B-ATF.
Jun/B-ATF heterodimers show a preference for binding AP-1 consensus DNA Members of the AP-1/ATF superfamily of transcription factors function as dimers that bind two closely related target DNA motifs called the AP-1 (or TRE) site (-TGA[C/G]TCA-) and the CRE site (-TGACGT-CA-). In many instances, there is preferred binding by dimers to one site over the other, and this is thought to provide a mechanism by which small changes in the (GAL4) 5 CAT reporter and 5 mg of the indicated GAL4 activator. The CAT activity in each cell extract is expressed as the fold-increase over the activity obtained from the GAL4 DB plasmid alone, which is set at 1.00. Expression of a GAL4 fusion protein containing the transcription activation domain of the adenovirus E1A transactivator was used as the positive control. Each value represents the average of at least three independent transfection experiments. Error bars indicate the standard deviation (s.d.) which is enumerated to the right of the bar graph level of particular bZIP proteins generate signi®cant changes in target promoter activation (Hai and Curran 1991) . B-ATF is a tissue-speci®c member of the AP-1/ ATF superfamily and forms dimers with the Jun proteins to bind AP-1 DNA (Dorsey et al., 1995) . To investigate the DNA binding preference of Jun/B-ATF complexes, electrophoretic mobility shift assays (EMSA) were performed using 32 P-labeled AP-1 (TRE) or CRE oligonucleotides. In vitro transcribed and translated B-ATF and JunB proteins were used to generate protein/DNA complexes that were resolved by electrophoresis through native polyacrylamide gels and visualized by autoradiography. Previously, we demonstrated that Jun/B-ATF heterodimers display strong binding to AP-1 DNA (Dorsey et al., 1995) . In this study, we have extended this observation and now show that this binding is competed eciently by adding excess unlabeled AP-1 DNA, is reduced modestly by CRE DNA and is not aected at all by competing with the unrelated consensus target DNA for the muscle regulatory factors (MRF) ( Figure 4A ). JunB/B-ATF complexes also bind labeled CRE DNA ( Figure 4A ), although the binding is weaker and is competed eciently by both the homologous CRE and the heterologous AP-1 oligonucleotides. In Figure 4B , the relative anity of JunB/B-ATF complexes for AP-1 versus CRE DNA is compared using competition EMSA. While a 50% reduction in AP-1 binding is obvious when a tenfold molar excess of unlabeled AP-1 DNA is added, there is no signi®cant decrease in AP-1 binding until 50-or 100-fold excess of CRE DNA is added. These data demonstrate that JunB/B-ATF complexes behave similarly to Jun/Jun or Jun/Fos complexes and show a preferred binding to AP-1 DNA.
Additional in vitro evidence for the shared preference of Jun/B-ATF and Jun/Fos complexes for AP-1 target DNA was obtained by competition EMSA using the wildtype AP-1 oligonucleotide and two non-consensus AP-1 oligonucleotides. AP-1 mut1 contains an A to T transversion in the last position of the AP-1 core consensus and AP-1 mut2 contains a C to A transition at position 6 of the core. These nucleotide changes have been implicated in the dierential binding of AP-1 complexes to DNA in vitro (Bohmann et al., 1987) . As shown in Figure 5 , the competition pro®le of the Jun/ B-ATF shifted complex with the mut1 and mut2 oligonucleotides re¯ects the behavior of the Jun/Fos complex assayed in parallel with the same competitors.
B-ATF inhibits transcription activation by AP-1
The shared DNA binding preference of Jun/B-ATF and Jun/Fos complexes, coupled with the results of the GAL4 transcription assays (Figure 2 ), suggests that B-ATF competes with other AP-1 family members (e.g., Fos) for the intracellular pool of Jun and generates DNA binding complexes that display a reduced transactivation potential. To test this hypothesis, 3TRE-Lux, a luciferase reporter gene controlled by three tandem AP-1 consensus sites, was used to measure AP-1 activity in mouse F9 teratocarcinoma cells ( Figure 6 ) as described in Materials and methods. F9 cells display a low level of endogenous AP-1 activity and thus have been used extensively to investigate transcription activation by AP-1 components (Angel and . As shown in Figure 6A , the 3TRE-Lux reporter shows measurable basal expression in F9 cells which is increased twofold following the addition of c-Fos. In the presence of B-ATF, c-Fos activation was reduced by 50%, supporting the hypothesis that B-ATF interferes with the formation of transcriptionally active (i.e., Jun/Fos) AP-1 complexes. Expression of B-ATF in the absence of co-transfected c-Fos results in a consistent 30% decrease in the basal activity of the luciferase reporter gene, which again suggests that B-ATF disrupts the basal activity of AP-1 complexes in F9 cells. The ability of B-ATF to inhibit AP-1 mediated transactivation was tested further by transfecting F9 cells with a set amount of c-Fos expression vector (1 mg) and increasing amounts of pEMscribe B-ATF (0.4 ± 10 mg) ( Figure 6B ). As predicted, the levels of 3TRE-Lux reporter gene expression decreased as the relative input Figure 3 Two-hybrid interaction of JunB and B-ATF in C3H10T1/2 cells. C3H10T1/2 cells were transiently transfected with 5 mg of the (GAL4) 5 CAT reporter, 5 mg of the indicated GAL4 DB plasmids and 5 mg of each plasmid encoding various subregions of B-ATF fused to the transcription activation domain (TAD) of VP16. The CAT activity in each cell extract is expressed relative to the level of activity measured for the monomeric GAL4 DB-VP16 which is set at 100%. Each value represents the average of at least three independent determinations and the error bars indicate standard error (s.e.) which is enumerated to the right of the bar graph Oncogene B-ATF functions as a dominant-negative to AP-1 DR Echlin et al of B-ATF to c-Fos DNA is increased. Control experiments demonstrate that increasing levels of the basic helix ± loop ± helix transcription factor Mist1 does not reduce AP-1-mediated transactivation by c-Fos ( Figure 6C ) and that B-ATF does not inhibit the expression of non-AP-1 regulated reporter genes under similar experimental conditions (Wang et al., 1999) .
If B-ATF functions as a non-activating competitor of c-Fos in the AP-1 dimer, it follows that a chimeric protein consisting of B-ATF and the TAD from VP16 should augment the transactivation of AP-1 reporter genes. For these experiments, C3H10T1/2 cells were transfected with 3TRE-Lux and expression vectors for The ability of B-ATF to block endogenous AP-1 transactivation can be tested by examining the eects of B-ATF in cell growth and transformation assays where the importance of AP-1 activity is welldocumented (Lloyd et al., 1991; Smeal et al., 1991; Vandel et al., 1996; Johnson et al., 1996) . We generated a C3H10T1/2 cell line, B-ATF-4, stably expressing moderate levels of a hemaglutinin-antigen (HA)-tagged human B-ATF protein and compared the growth of this cell line to wildtype C3H10T1/2 cells and to a previously characterized C3H10T1/2 cell line expressing oncogenic Ras p21 (see Materials and methods for details) ( Figure 8A ). The linear growth of the C3H10T1/2 culture reached saturation density on day 6 after plating with a total cell count of approximately 1610 6 cells/60 mm dish. Ras neo 11A cells, which display similar growth kinetics as C3H10T1/2 cells, are not contacted-inhibited and grow to a saturation density that is threefold higher than the wildtype cells. The B-ATF-4 cell line displays dierent growth kinetics, yet reaches the same saturation density as control cells by day 10 of the experiment. Two additional B-ATF expressing C3H10T1/2 cell lines generated in this study also display a similar slow growth phenotype (data not shown).
The ability to establish several B-ATF expressing cell lines for long term study suggests that forced expression of B-ATF is not toxic to C3H10T1/2 cells. To demonstrate this directly, we stably transfected C3H10T1/2 cells with pDCR, a vector carrying a neomycin resistance gene cassette or with the pDCR vector also expressing HA-tagged B-ATF (pDCR-B-ATF). After 14 days of growth in selective medium, the cultures were ®xed, stained with Giemsa and the resulting colonies were counted. For both groups, the total number of G-418 resistant colonies was equiva- not shown) , yet the appearance of the control colonies was dramatically dierent when compared to the B-ATF colonies ( Figure 8B ). C3H10T1/2-B-ATF colonies are more sparsely populated and less densely packed than the control colonies. These results support the growth curve studies using, in this case, a mixed population of cell clones expressing B-ATF. We conclude that while B-ATF expressing C3H10T1/2 cells remain viable, the cell cycle is altered such that their generation time is lengthened signi®-cantly.
To further examine the role of B-ATF as a negative regulator of AP-1-mediated activities, cellular transformation by activated human H-Ras p21 in the presence or absence of B-ATF was analysed. AP-1 function is required for Ras-induced cellular transformation (Lloyd et al., 1991; Smeal et al., 1991; Vandel et al., 1996; Johnson et al., 1996) and we wanted to test the potential of B-ATF to counteract Ras-stimulated cell growth and transformation. Having at our disposal the Figure 6 B-ATF inhibits transactivation of an AP-1 reporter gene in vivo. (A) F9 teratocarcinoma cells were transiently transfected with 1 mg of the 3TRE-Lux reporter gene, 2.5 mg of pEMscribe c-fos and/or pEMscribe B-ATF, and 0.5 mg of RSVlacZ to control for transfection eciency. The total input of DNA in all groups was kept constant (6.5 mg) by adding the appropriate amount of pEMSVscribea-2 vector DNA. Forty-eight hours posttransfection, cell extracts were prepared. Luciferase activity and bgalactosidase activity were determined as described in Materials and methods. Results are expressed relative to the luciferase activity in the c-Fos group which is set at 100. Each value represents the average of six independent experiments. Error bars represent the standard error of the mean. (B) F9 cells were transfected as described above with 1 mg of 3TRE-Lux, 1 mg of pEMscribe c-fos, 0.5 mg of RSV-lacZ, the indicated amount of pEMscribe B-ATF and the appropriate amount of pEMSVscribea-2 vector DNA to adjust plasmid input to 12.5 mg per group. Results are expressed relative to the luciferase activity in the c-Fos control group which is set at 100. Each value represents the average of at least three independent experiments. Error bars represent the standard error of the mean. (C) Control experiment performed using the basic ± helix ± loop ± helix transcription factor Mist1. The amounts of reporter, RSV-lacZ, pEMscribe c-fos, pcDNA3-Mist1 and pcDNA3 vector DNA are as indicated in (B). Each value represents the average of three independent determinations. Error bars represent the standard error of the mean Figure 7 A B-ATF TAD fusion protein activates AP-1 reporter gene activity. C3H10T1/2 cells were transiently transfected with 1 mg of the 3TRE-Lux reporter, 0.5 mg of RSV-lacZ and 2.5 mg of pNLVP (VP16 TAD), pEMscribe B-ATF (B-ATF) or B-ATF TAD in the presence or absence of pEMscribe c-fos and pEMscribe c-jun (0.25 mg of each). The total amount of DNA per transfection group was kept constant by the addition of pEMSVscribea-2 vector DNA. Forty-eight hours after transfection, cells extracts were prepared and assayed for luciferase and bgalactosidase activity as described previously. Results are expressed as the fold-increase over the luciferase activity measured for 3TRE-Lux in the presence of pNLVP alone which is set at 1.0. Each value represents the average of six independent experiments. Error bars indicate the standard error of the mean Per cent focus formation is calculated within each experimental group by setting the number of foci obtained with H-Ras alone to 100%. The eciency of focus formation for each group represents the average of per cents calculated from individual experiments. The standard error of the mean (s.e.m.) for each group is noted in parentheses Oncogene B-ATF functions as a dominant-negative to AP-1 DR Echlin et al B-ATF TAD construct (Figure 7) , we also were interested in examining if this arti®cial AP-1`activator' would augment Ras transformation or perhaps function as a transforming protein on its own. C3H10T1/2 cells were stably transfected with pT24H-ras and either pDCR vector, pDCR-B-ATF, or B-ATF TAD. Cells were maintained in reduced serum for a minimum of 14 days after which time the cultures were ®xed, stained and scored for focus formation. Table 1 lists the number of transformation events scored in individual experiments. No spontaneous foci formed in the control plates and B-ATF expression alone did not transform C3H10T1/2 cells. H-Ras expression induces a moderate level of focus formation (set to 100%) which is reduced by approximately 50% in the presence of pDCR-B-ATF. We believe that this reduced level of focus formation is due to the inhibition of the Ras transformed phenotype, rather than to the general suppression of cell growth as described above, since two plates from the H-Ras plus B-ATF group were maintained for an additional 7 days following transfection (21 days total) and showed no evidence of slow-growing, microscopic foci that would be able to account for the reduced number of foci overall. Interestingly, transfection of C3H10T1/2 cells with the B-ATF TAD expression vector did not cause focus formation on its own, yet increased Rasmediated focus formation by approximately 2.5-fold, indicating that AP-1 activation is necessary, but not sucient, to produce this biological phenomenon.
As a more direct test of the ability of B-ATF to inhibit cellular transformation events relying on AP-1 activity, C3H10T1/2 cells were stably transfected with FBJ/R v-fos, pCDR-B-ATF, or FBJ/R v-fos and pDCR-B-ATF as described in Materials and methods. 
Discussion
In this paper, we have characterized the activities of B-ATF, a relatively new member of the AP-1 transcription factor family. Analyses of the mRNA encoding B-ATF reveals that the 0.9 bp transcript is expressed predominantly in hematopoietic tissues and represents the full-length transcript of a single gene (Dorsey et al., 1995; Meyer et al., 1998) . In humans, the highest level of B-ATF mRNA is detected in circulating T cells and in EBV-infected B lymphocytes (Johansen and Taparowsky, manuscript in preparation). In the mouse, a more detailed analysis of B-ATF mRNA and protein expression has been performed and reveals a dierential expression of B-ATF during discrete stages of T cell development in the thymus and constitutive expression of B-ATF in B lymphocytes (Williams and Taparowsky, unpublished observations). The role of AP-1 complexes in the immune system is welldocumented (reviewed in Foletta et al., 1998) , in¯uen-cing a myriad of growth and dierentiation decisions relating to the development and function of hematopoietic cells. As a result, it was of paramount importance to explore the biochemical properties of B-ATF in order to assess how its presence or absence may in¯uence cellular AP-1 activity.
We have shown previously that B-ATF does not form homodimers and preferentially forms heterodimers with all three members of the Jun family of bZIP proteins. In this study, we extended this observation to show that heterodimer formation relies on the leucine zipper of B-ATF and that the DNA binding site preference for Jun/B-ATF dimers is strikingly similar to that of Jun/Fos dimers. This strongly suggests that in cellular situations where B-ATF, Fos and Jun are co-expressed, B-ATF competes with Fos for the available pool of Jun and forms dimers that will occupy the same target DNA. However, in contrast to Fos, B-ATF does not possess a conventional transcription activation domain and thus suggests that the competition between B-ATF and Fos for the transcriptionally active members of the Jun protein family Figure 9 B-ATF inhibits cellular transformation by v-Fos. Standard C3H10T1/2 focus assays were performed as described in Materials and methods. In this experiment, cultures were scored for focus formation 21 days following transfection due to the small, compact phenotype of v-Fos foci. A representative plate from each experimental group is pictured. Note the dramatic reduction in the number of foci when v-Fos is coexpressed with B-ATF (primarily JunB and c-Jun) will have a dramatic eect on AP-1 target gene expression. Indeed, while Jun/Fos complexes activate transcription from the 3TRE-Lux reporter gene, we have observed that the expression of exogenous B-ATF inhibits AP-1 reporter gene activity in cells. Furthermore, we generated a B-ATF protein fused to the potent transcription activation domain of VP16 and demonstrated that this chimeric molecule exerts a positive impact on 3TRE-Lux reporter gene expression. The transcriptional eects of B-ATF on this arti®cial AP-1 reporter gene have been observed in two dierent cell lines and have been duplicated in separate studies (Burg and Taparowsky, manuscript in preparation) using human T lymphocytes and the tissue-speci®c GM-CSF reporter gene which is regulated by the cooperative interaction between AP-1 and Ets transcription factors (Wang et al., 1994) .
Our simple interpretation of the observed eects of B-ATF on reporter gene activity is that B-ATF functions as a dominant-negative to AP-1. In an attempt to utilize B-ATF as a biological reagent to block cellular processes that have been shown to rely on the positive activation of AP-1 (Lloyd et al., 1991; Smeal et al., 1991; Vandel et al., 1996; Johnson et al., 1996) , we used C3H10T1/2 focus assays to test if B-ATF would inhibit transformation induced by the expression of oncogenic H-Ras of v-Fos. In both cases, B-ATF expression resulted in a reduced number of foci compared to controls. This suggests that the in¯uence of H-Ras and v-Fos on the growth and morphology of cells can be counteracted by B-ATF, presumably through its negative eect on Jun-mediated transactivation. Support for this conclusion was obtained from the analysis of C3H10T1/2 cells overexpressing B-ATF, which remain viable yet display a slow growth phenotype, again suggesting that B-ATF impairs the function of AP-1. Interestingly, while the transcriptionally active B-ATF-TAD construct was able to augment transformation by activated H-Ras, it did not perform equivalently to v-Fos and was unable to cause focus formation on its own. This may be a consequence of dierences in the protein-protein interactions speci®ed by the TADs of VP16 and Fos, or to additional mutations in v-Fos that augment its activity. In this regard, we have not observed focus formation following the overexpression of the c-Fos protein in C3H10T1/2 cells (Tae and Taparowsky, unpublished observations). In analysing the results of these culture experiments, we are encouraged by the slow growth phenotype of the B-ATF-4 cell line since it is similar to that described for c-jun7/7 null ®broblasts (Johnson et al., 1993; Schreiber et al., 1999) . Additional experiments to characterize the cell cycle of B-ATF-4 cells and to examine potential changes in the expression of AP-1 target genes such as p53 (Schreiber et al., 1999) and cyclin D1 (Wisdom et al., 1999) are underway.
The B-ATF protein represents the ®rst bZIP protein, encoded by the full-length transcript of a distinct gene (Meyer et al., 1998) , that has been shown to function as a dominant-negative to AP-1 by forming transcriptionally inert dimers with the Jun family of proteins. Earlier studies by a number of labs sought to design synthetic dominant-negatives to AP-1 by removing the TAD of Fos (Wick et al., 1992; Brown et al., 1994) or Jun (Lloyd et al., 1991; Brown et al., 1993) , or by replacing the basic region of Fos with an acidic extension (Olive et al., 1997) . These arti®cial molecules function as predicted and in a direct comparison, duplicate the eects of B-ATF on AP-1 reporter gene activity and in C3H10T1/2 focus assays (Olive et al., 1997; Echlin and Taparowsky, unpublished observations) .
In 1997, Aronheim et al. identi®ed a protein in rat pituitary cells called JDP-1 whose sequence similarity to B-ATF suggests that it too will function as an inhibitor of AP-1 (Aronheim et al., 1997) . The existence of at least two distinct bZIP molecules with this property reveals a new mechanism for controlling AP-1 activity that is similar to the role of dominantnegative ICER proteins in regulating members of the CREB/ATF family of proteins (reviewed in SassoneCorsi et al., 1995) or the DFosB (FosB2) protein, the product of an alternatively spliced mRNA from the mouse fosB gene (Nakabeppu and Nathans, 1991; Carrozza et al., 1997) , in regulating AP-1 (Nakabeppu and Nathans, 1991; Carrozza et al., 1997) . In addition, the existence of B-ATF and JDP-1 has provided us with the opportunity to compare the bZIP regions of these inhibitors with the bZIP regions of other AP-1 family members. Interestingly, the basic regions of both B-ATF and JDP-1 contain a serine in place of a conserved cysteine residue that is responsible for the redox-regulated DNA binding properties of AP-1 (reviewed in Xanthoudakis and Curran, 1996) . The post-translational modi®cation of B-ATF in vivo and the potential impact of various modi®cations on dimerization and DNA binding is the subject of future studies and will help to de®ne the cellular conditions required for B-ATF to eciently block the activity of Jun containing AP-1 protein complexes.
Materials and methods
Plasmid constructions
The GAL4 (1 ± 147) vector, which contains the DNA binding domain (DB) of the yeast activator protein GAL4, the (GAL4) 5 E1B TATA CAT reporter and the chimeric activators, GAL4 DB-E1A and GAL4 DB-VP16, have been described previously (Min et al., 1994) . GAL4 DB B-ATF (1 ± 125) was constructed by inserting the EcoRI/XbaI fragment from pBS-B-ATF (Dorsey et al., 1995) into EcoRI/XbaI-linearized GAL4 (1 ± 147). Portions of the B-ATF cDNA spanning residues 1 ± 32 and 81 ± 125,¯anked by 5' EcoR1 and 3' XbaI restriction sites, were generated by PCR ampli®cation and cloned into EcoRI/XbaI-restricted GAL4 (1 ± 147) to create GAL4 DB-B-ATF (1 ± 32) and GAL4 DB-B-ATF (81 ± 125). GAL4 DB-JunB was constructed by excising the junB cDNA from pBS-junB (Dorsey et al., 1995) with EcoRI and XbaI and cloning the fragment into GAL4 (1 ± 147). Regions of the B-ATF cDNA were ampli®ed by PCR with primers designed to provide 5' EcoRI and 3' XbaI restriction sites and subcloned into pBS-KS + (Stratagene, La Jolla, CA, USA) to generate pBS-B-ATF (1 ± 125), pBS-B-ATF (1 ± 31), pBS-B-ATF (1 ± 50) and pBS-B-ATF (49 ± 125). The pBS-B-ATF plasmids were restricted with XhoI and XbaI and the inserts subcloned into pNLVP (Dang et al., 1991) to generate TAD-B-ATF (1 ± 125), TAD-B-ATF (1 ± 31), TAD-B-ATF (1 ± 50) and TAD-B-ATF (49 ± 125). pEMscribe B-ATF contains the human B-ATF coding region modi®ed with EcoRI linkers prior to insertion into EcoRI-linearized pEMSVscribea-2 (Davis et al., 1987) . pEMscribe c-jun and pEMscribe c-fos were constructed similarly using the rat pSP65 c-jun and c-fos cDNAs as the starting material (gift of S Konieczny, Purdue University). The 3TRE-Lux reporter (gift of J Massague, Howard Hughes Medical Institute Research Laboratories, Memorial SloanKettering Cancer Center, New York, NY, USA) contains three tandem TRE elements inserted upstream of a minimal TATA box promoter which drives expression of the ®re¯y luciferase gene. RSV-lacZ, the b-galactosidase expression plasmid used to normalize transfection eciency, has been described previously (Min et al., 1994) , as have the pDCR and pDCR-B-ATF DNAs (Dorsey et al., 1995) and the pcDNA3 and pcDNA3-Mist1 plasmids (Lemercier et al., 1997) . B-ATFTAD was generated from a three-part ligation using a PCR ampli®ed B-ATF cDNA fragment, tailed with EcoRI and ClaI restriction sites, a PCR ampli®ed VP16 TAD fragment tailed with ClaI and XbaI restriction sites, and EcoRI/XbaI-cleaved pcDNA3 (Invitrogen; Carlsbad, CA, USA). In B-ATFTAD, the VP16 TAD is expressed as an in-frame fusion at the carboxyl terminus of B-ATF. The FBJ/R v-fos and pT24 H-ras plasmids used for the C3H10T1/2 focus assays have been described previously (Miller et al., 1985; Taparowsky et al., 1982) .
Northern blot hybridization
A human immune system Multiple Tissue Northern (MTN) blot (Clontech, Palo Alto, CA, USA) was hybridized with a 32 P-labeled B-ATF cDNA probe using the hybridization and wash conditions described in Dorsey et al. (1995) . The hybridized ®lter was stripped as described in Davenport and Taparowsky (1992) and rehybridized as above using a 32 Plabeled human junB cDNA fragment obtained from the SmaI/XbaI digestion of pBS-junB and a 32 P-labeled G 3 PDH DNA probe (Clonetech).
Cell culture and transfection C3H10T1/2 mouse ®broblasts (American Type Tissue Culture Collection, CCL226, Rockville, MD, USA) were maintained in basal modi®ed Eagle medium (BME) (GIBCO/ BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Bio-Whittaker, Walkersville, MD, USA), penicillin (100 U/ml) and streptomycin (100 mg/ml). For the focus assays, the BME was supplemented to 5% with fetal bovine serum; for the colony assays, 400 mg/ml G-418 (GIBCO/BRL) was added to complete growth medium. The ras neo 11A (Teegarden et al., 1990 ) and B-ATF-4 cell lines were derived from C3H10T1/2 cells and maintained in growth medium supplemented with 400 mg/ml G-418. F9 teratocarcinoma cells (American Type Tissue Culture Collection, CRL1720) were maintained in Dulbecco's high glucose modi®ed Eagle medium (HG-DMEM) (GIBCO/BRL) containing 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 mg/ml).
Transient cell transfections were carried out using calcium phosphate-DNA precipitation as described previously (Min et al., 1992) with the amounts of plasmid DNA indicated in the Figure legends . DNA precipitates were incubated with cells for 5 h, after which the cells were shocked osmotically with 20% glycerol in unsupplemented BME or HG-DMEM for 2 min and then maintained in complete growth medium for an additional 48 h. Cell extracts were prepared, normalized for b-galactosidase activity, and assayed for chloramphenicol acetyl transferase (CAT) activity or for luciferase activity as previously described (Min and Taparowsky 1992; Ramocki et al., 1997) .
C3H10T1/2 colony assays were performed as described previously (Min et al., 1994) . Brie¯y, C3H10T1/2 cells were seeded 24 h prior to transfection at 5610 5 C3H10T1/2 cells per 100 mm culture dish and treated 2 h prior to transfection with complete growth medium containing 10 mg/ml chloroquine (Sigma, St. Louis, MO, USA). Individual calcium phosphate-DNA precipitates containing 30 mg of C3H10T1/2 carrier DNA and either 50 ng of pDCR or pDCR-B-ATF were added to each of two plates. Twenty-four hours after transfection, the cultures were passaged 1 : 6 and maintained in medium supplemented with G-418. After 14 days, the cultures were ®xed with 100% methanol for 10 min and stained with Giemsa (EM Diagnostic Systems, Gibbstown, NJ) to establish the eciency of colony formation. Individual colonies from live cultures were photographed and then selected using cloning cylinders, expanded in culture and analysed for the expression of exogenous B-ATF by Western blot hybridization with HA antiserum (Boehringer Mannheim, Indianapolis, IN, USA) as described previously (Ramocki et al., 1997) .
Focus assays were performed as described previously (Min et al., 1994) . Individual precipitates containing 30 mg of carrier DNA and the indicated combinations of 100 ng pT24 H-ras and 300 ng of each B-ATF plasmid DNA, or 250 ng of v-fos DNA and 1.25 mg of B-ATF DNA were added to each of two plates. The increased amount of DNA used for the Fos transfections was necessary in order to provide a more dramatic contrast in focus formation, given that the small, compact phenotype of v-fos-induced C3H10T1/2 foci are dicult to count (see Figure 9 ). Twenty-four hours after transfection, the cultures were passaged 1 : 3 and maintained in reduced serum medium. Fourteen to 21 days after passaging, the plates were ®xed and stained with Giemsa as described above and the number of foci per experimental group tabulated.
For the growth curve, C3H10T1/2 cells, ras neo 11A cells and B-ATF-4 cells were plated in growth medium at a density of 1610 4 cells per 60 mm culture dish on day 0. The growth medium was changed on day 1, day 4 and day 7. Cell counts for duplicate plates for each cell line were determined daily starting on day 2.
Electrophoretic mobility shift assays (EMSA)
Proteins used for EMSA were generated by in vitro transcription and translation. The human junB, c-fos, and B-ATF cDNAs in pBS-KS + and the human c-jun cDNA in pEMSVscribea-2 were linearized and 5 mg of each DNA used with the MAXIscript in vitro Transcription Kit (Ambion, Austin, TX, USA) to produce m 7 GpppG-capped RNA. Proteins were produced by in vitro translation in rabbit reticulocyte lysates (Promega, Madison, WI, USA) and protein quanti®ed in parallel reactions supplemented with L-[ 35 S]methionine (4800 Ci/mmol; Amersham Pharmacia Biotech, Piscataway, NJ, USA). Using sequence information provided by a number of commercial sources, doublestranded DNA containing consensus AP-1 (5'-AGCTTCGCTTGATGAGTCAGCCG-3'), mutant AP-1 ( Figure 5 ) or CRE (5'-GATCCAGAGATTGCCTGACGT-CAGAGAGCTA-3') motifs were synthesized and end-labeled using T4 polynucleotide kinase and [g-32 P]dATP (6000 Ci/ mmol; Amersham Pharmacia Biotech). All DNA probes were separated from unincorporated nucleotides using the spin column procedure (Sambrook et al., 1989) . Approximately 2610 5 c.p.m. of each DNA probe was incubated at RT for 20 min with 4 ml total volume of each in vitro translated protein in a reaction mixture containing 25 mM HEPES (pH 7.9), 50 mM potassium chloride, 5 mM dithiothreitol, 5 mM magnesium chloride, 0.5 mM EDTA and 10% glycerol. For competition EMSA, unlabeled AP-1, mutant AP-1, CRE or double-stranded MRF DNA (5'-GATCCGTCTGAGGAGA-CAGCTGCAGCTCCA-3') was added prior to the addition of the labeled probe. Binding reactions were electrophoresed through a 4% nondenaturing polyacrylamide gel at 100 V for 3 h in 12.5 mM Tris-HCl (pH 8.5), 95 mM glycine and 0.5 mM EDTA. The gels were dried and exposed to X-ray ®lm overnight at 7808C with an intensifying screen.
